Georgia Retina has a long history of commitment to and participation in clinical trials in order to provide our patients access to new, state-of-the-art preventative, or therapeutic treatments. We partner with the National Eye Institute, some of the nation’s top pharmaceutical companies, and other clinical practices to explore the causes and cures for many retinal conditions.
We take special care to ensure that our study patients experience the best medical care possible.
About Our Research
Georgia Retina continues its dedication to the advancement of ophthalmic science and patient care through the active participation in well-designed, randomized, controlled clinical trials. Participation in clinical research trials helps to bring new and innovative therapies for many blinding conditions into clinical practice and to our patients.
If you are interested in determining your eligibility for a trial, please contact our Clinical Research Coordinator, Leslie Marcus, CCRC at (404) 299-5209.
Wet Age-Related Macular Degeneration
Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Allergan 190342-038 BEACON
- Roche GX29176 CHROMA
- Genentech, Inc. GR39821
- Ophthotech OPH2003
- Roche GX30191 OMASPECT
Retinal Vein Occlusion
Diabetic Macular Edema
Nonproliferative Diabetic Retinopathy
- AART C-02-60
- Acucela 4429-202 SEATTLE
- ALLERGAN 206207-012
- AREDS2 ForeseeHome
- C-09-067 RACE
- DRCR.net Protocol N
- HORIZON FVF3426g
- MARINA FVF2598g
- Novartis CSPP100A2244
- Ocriplasmin Research to Better Inform Treatment (ORBIT)
- Regeneron R2176-3-AMD-1417 CAPELLA
- RIDE FVF4168g
- RISE FVF4170g
- SAILOR FVF3689g
- Suprachoroidal Buckling for Retinal Detachment